Bayers, Sunharbo

Bayer's Sunharbo Launch Timetable Set as Deutsche Bank Raises Target to EUR 65

Published on 11/18/2026 at 03:50 | Editorial boerse-global.de
Bayer confirms US shipments of newly approved stroke drug Sunharbo for mid-to-late November, as analysts weigh pipeline risk and generic pressure on Xarelto.
Bayers, Sunharbo, Launch, Timetable, Set, Bank, Raises, Target, EUR, Bayer Illustration mit AI erstellt.

Bayer has confirmed that shipments of its newly approved stroke drug will begin in the US between mid and late November, giving the German group a concrete commercial timeline for the medicine it is counting on to offset declining sales of its bestseller Xarelto.

The FDA cleared Asundexian under the brand name Sunharbo in the past week for reducing the risk of further strokes in certain adults, to be used in combination with an antiplatelet agent. Bayer described it as the world's first approved factor XIa inhibitor. Sebastian Guth, head of Bayer's US operations, last week called the drug an important building block of the company's US growth strategy, according to Handelsblatt.

Jefferies Sees Pipeline Risk Easing, Keeps Hold

Jefferies analyst Michael Leuchten wrote on Tuesday of last week that the approval substantially lowers the risk attached to Bayer's pharmaceutical pipeline. The research house reiterated its hold rating and its EUR 48.50 price target.

Deutsche Bank took a more bullish line the same day, lifting its target to EUR 65.00 from EUR 60.00 while maintaining a buy recommendation. The upgrade rested on a better-than-expected third quarter and higher estimates for the fourth quarter, both driven by the pharmaceuticals division. The bank raised its 2026 EBITDA forecast by roughly 3% to EUR 10.1 billion.

Should investors sell immediately? Or is it worth buying Bayer?

A Quarterly Loss Alongside an Improved Outlook

The analyst moves followed Bayer's 3 November release of third-quarter 2026 figures, which showed a group net loss of EUR 672 million even as EBITDA before special items came in positive at EUR 1.62 billion. Revenue for the period reached EUR 10.1 billion.

Alongside the numbers, Bayer raised its guidance for the pharmaceuticals margin and for free cash flow, and said it expects lower net financial debt. For full-year adjusted group EBITDA, the company lifted its range to EUR 9.8 billion to EUR 10.3 billion, up from a previous EUR 9.6 billion to EUR 10.1 billion. It also said it expects sales growth in the pharmaceuticals division to land at the upper end of its forecast range.

DZ Bank responded on 5 November by raising its fair value for Bayer to EUR 64 from EUR 60 and confirming its buy recommendation. Analyst Peter Spengler pointed to operational stabilisation, debt reduction and progress on US legal risks as the basis for the move.

Bayer at a turning point? This analysis reveals what investors need to know now.

Generics Pressure Makes New Growth Essential

The flurry of analyst activity underscores what is at stake for Bayer's pharmaceutical business, which must generate fresh growth to absorb revenue declines caused by generic competition. Asundexian is central to that effort, with Bayer aiming to use it to counter the erosion of Xarelto. The company has now secured the approval and set a delivery window; the task ahead is converting both into the sales contribution its growth story depends on.

Ad

Bayer Stock: New Analysis - 18 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70529251 |